MET and neoplasm: However, e.g., abnormal c-Met activation in the epithelial tumor cells (Table S1a, and Figures S1 aiii, and biii) indicates that additional factors might be involved in the poor immunotherapeutic prognosis in sMDI JA-0009 [90].